Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Merit Medical (MMSI) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and ou ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aurinia Pharmaceuticals (AUPH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Aurinia Pharmaceuticals is one of 947 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks S ...

The Cooper Companies (COO) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.60%. A quarter ago, it was expected that this surgical and contact lens products maker would post earnings of $1.07 per share when it actually produced earnings of $1.1, delivering a surprise of +2.8%.Over t ...

Core Viewpoint - Aurinia Pharmaceuticals (AUPH) is currently outperforming its peers in the Medical sector, with a year-to-date return of 74.6% compared to the sector average of 6.3% [4]. Company Performance - Aurinia Pharmaceuticals is ranked 4 in the Zacks Sector Rank among 949 companies in the Medical group [2]. - The Zacks Rank for AUPH is 2 (Buy), indicating a positive earnings outlook [3]. - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% in the past quarter, reflecting stronger analyst sentiment [4]. Industry Context - AUPH is part of the Medical - Drugs industry, which consists of 144 companies and is currently ranked 75 in the Zacks Industry Rank [6]. - The average return for stocks in the Medical - Drugs industry this year is 6.1%, indicating that AUPH is performing significantly better [6]. - Another outperforming stock in the Medical sector is Cardinal Health (CAH), which has a year-to-date return of 77.1% and a Zacks Rank of 2 (Buy) [5].

Core Insights - Cardinal Health (CAH) shares have increased by 29.4% over the past month, reaching a new 52-week high of $210.33, and have gained 77.1% since the start of the year, outperforming the Zacks Medical sector and the Zacks Medical - Dental Supplies industry [1] Financial Performance - Cardinal Health has consistently beaten earnings estimates, reporting EPS of $2.55 against a consensus estimate of $2.21 in its last earnings report on October 30, 2025, and exceeding revenue estimates by 8.39% [2] - For the current fiscal year, Cardinal is projected to achieve earnings of $9.86 per share on revenues of $258.58 billion, reflecting a 19.66% increase in EPS and a 16.18% increase in revenues. For the next fiscal year, earnings are expected to rise to $10.9 per share on revenues of $277.02 billion, indicating year-over-year changes of 10.53% and 7.13%, respectively [3] Valuation Metrics - Cardinal Health has a Value Score of A, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A, indicating strong potential for value investors [6] - The stock trades at 21.3 times current fiscal year EPS estimates, above the peer industry average of 15 times, and at 18 times trailing cash flow compared to a peer average of 12 times. The PEG ratio stands at 1.52, placing Cardinal in the top tier of stocks from a value perspective [7] Zacks Rank - Cardinal Health holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, making it a suitable choice for investors looking for stocks with strong potential [8] Industry Comparison - The Medical - Dental Supplies industry is performing well, ranking in the top 22% of all industries, providing favorable conditions for both Cardinal Health and its peer, McKesson Corporation (MCK), which also has a Zacks Rank of 2 (Buy) [11]

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - The Zacks Momentum Style Score helps investors identify stocks with strong momentum, addressing the challenges of defining momentum [2] Company Overview: Cardinal Health (CAH) - Cardinal Health currently holds a Momentum Style Score of A, indicating strong momentum potential [3] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4] Performance Metrics - Over the past week, CAH shares increased by 6.76%, while the Zacks Medical - Dental Supplies industry saw a slight decline of 0.03% [6] - In a longer timeframe, CAH's monthly price change is 29.83%, significantly outperforming the industry's 1.27% [6] - Over the last quarter, CAH shares rose by 36.13%, and over the past year, they increased by 68.94%, compared to the S&P 500's gains of 6.44% and 13.97%, respectively [7] Trading Volume - CAH's average 20-day trading volume is 2,610,722 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, 6 earnings estimates for CAH have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $9.45 to $9.79 [10] - For the next fiscal year, 5 estimates have also moved higher, indicating positive sentiment around CAH's earnings potential [10] Conclusion - Given the strong performance metrics and positive earnings outlook, CAH is positioned as a solid momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]

Core Insights - Investors in the Medical - Dental Supplies sector may consider Conmed (CNMD) and Merit Medical (MMSI) as potential value stocks [1] - A strong Zacks Rank combined with a good Value grade is identified as an effective strategy for finding value stocks [2] - Both CNMD and MMSI currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions [3] Valuation Metrics - CNMD has a forward P/E ratio of 9.88, while MMSI has a forward P/E of 23.47, suggesting CNMD may be undervalued [5] - The PEG ratio for CNMD is 1.50, compared to MMSI's PEG ratio of 2.39, indicating CNMD's better valuation relative to its expected earnings growth [5] - CNMD's P/B ratio is 1.36, while MMSI's P/B ratio is 3.35, further supporting CNMD's position as a more attractive value option [6] Conclusion - Based on the valuation metrics, CNMD is considered the superior value option compared to MMSI [7]

Group 1: Company Performance - Alkermes (ALKS) has shown a year-to-date performance increase of approximately 8%, outperforming the average return of 1.3% for Medical companies [4] - The Zacks Consensus Estimate for ALKS' full-year earnings has risen by 14.7% over the past 90 days, indicating a positive trend in analyst sentiment [3] - Alkermes holds a Zacks Rank of 1 (Strong Buy), suggesting strong potential for future performance [3] Group 2: Industry Context - Alkermes is part of the Medical - Biomedical and Genetics industry, which consists of 469 stocks and currently ranks 99 in the Zacks Industry Rank [5] - The Medical - Biomedical and Genetics industry has experienced an average gain of 11.4% this year, indicating that Alkermes is slightly underperforming its industry [5] - In contrast, Cardinal Health, which belongs to the Medical - Dental Supplies industry, has returned 66.4% year-to-date and has a Zacks Rank of 2 (Buy) [4][5]

Core Insights - Becton Dickinson (BDX) reported quarterly earnings of $3.96 per share, exceeding the Zacks Consensus Estimate of $3.92 per share, and showing an increase from $3.81 per share a year ago, representing an earnings surprise of +1.02% [1] - The company achieved revenues of $5.89 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.04% and up from $5.44 billion year-over-year [2] - Becton Dickinson has outperformed consensus EPS estimates in all four quarters over the past year, while it has topped revenue estimates three times in the same period [2] Earnings Outlook - The future performance of Becton Dickinson's stock will largely depend on management's commentary during the earnings call and the sustainability of its immediate price movement based on the latest earnings numbers and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.25 on revenues of $5.39 billion, and for the current fiscal year, it is $14.79 on revenues of $22.77 billion [7] Industry Context - The Medical - Dental Supplies industry, to which Becton Dickinson belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into potential stock performance [5]

Core Viewpoint - Conmed (CNMD) reported quarterly earnings of $1.08 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, and showing a slight increase from $1.05 per share a year ago, indicating a positive earnings surprise of +2.86% [1] Financial Performance - The company achieved revenues of $337.93 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.42% and reflecting a year-over-year increase from $316.7 million [2] - Over the last four quarters, Conmed has consistently exceeded consensus EPS and revenue estimates [2] Stock Performance - Conmed shares have declined approximately 33.2% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The current Zacks Rank for Conmed is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $1.31 on revenues of $368.68 million, and for the current fiscal year, it is $4.47 on revenues of $1.37 billion [7] - The trend of earnings estimate revisions for Conmed was mixed prior to the earnings release, which may influence future stock performance [6] Industry Context - The Medical - Dental Supplies industry, to which Conmed belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]